---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009664"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:23:43.235235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q1 revenue $32.9M (+18% YoY), net income $58K, raises FY2025 guidance to $127-131M

## Summary
- Revenue $32.9M, up 18% vs Q1 2024; net income $58K vs net loss $4.4M prior year.
- Adjusted EBITDA $3.0M vs loss $1.0M; cash from operations $1.3M vs use of $5.8M.
- FY2025 revenue guidance raised to $127-131M (8-12% growth) from prior $126-130M.
- Launched Trivium next-generation DBM allograft; elevated Mark Schallenberger to COO.
- Terminated investor rights agreement with OrbiMed; completed secondary share sale led by Nantahala.

## SEC filing metadata
- accession: 0001641172-25-009664
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000164117225009664/0001641172-25-009664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000164117225009664/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009664
- JSON: https://secwatch.observer/filing/0001641172-25-009664.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.